HEIDELBERG, Germany and MEDFORD, Mass., Dec. 6 /PRNewswire/ -- febit holding gmbh today announced the addition of David Mahoney to the newly created position of director of global intellectual property and U.S. legal affairs.
As director of global intellectual property and U.S. legal affairs, Mahoney will be based in febit’s U.S. offices and will be responsible for managing U.S. legal matters and the intellectual property portfolio of the febit group. Mahoney brings to febit experience in international intellectual property management, encompassing corporate litigation matters and licensing issues. Prior to joining febit, Mahoney was U.S. director of legal affairs for Sygnis Pharma AG. He is also registered to practice before the U.S. Patent and Trademark Office.
“The addition of David Mahoney to febit is an important step as we continue with the development of highly innovative technologies for genomic research,” said Cord F. Staehler, president and CEO of febit holding gmbh. “febit currently holds more than 20 patents and patent applications for bioanalytics and the manufacture of synthetic genes on biochips, and we plan to continue with significant advances in this area.”
“Safeguarding intellectual properties and rights of use by potent IP strategies and comprehensive patent protection is vital in the dynamic and competitive biotechnology market,” said Mahoney. “I am pleased to join febit in the ongoing development of highly innovative technologies.”
For more information please visit www.febit.eu.
About febit & Geniom
Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications (Geno-, SNP- and Pathogentyping, Enzyme- on-Chip, miRNA-Profiling and many more). With the unique Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.
david.schull@russopartnersllc.comeva.sterzel@febit.de wendy.lau@russopartnersllc.com
CONTACT: Eva Sterzel, Public Relations Manager of febit holding gmbh,
+49-6221-6510-300, eva.sterzel@febit.de; David Schull,
david.schull@russopartnersllc.com, or Wendy Lau,
wendy.lau@russopartnersllc.com, +1-212-845-4271, both of Russo Partners
LLC, for febit holding gmbh
Web site: http://www.febit.eu/
